Accuray Incorp Stock Price, News & Analysis

Accuray Incorporated (NASDAQ: ARAY) reported a record net revenue of $116.3 million for Q2 FY2022, up 19% year-over-year. Gross orders reached $85.4 million, a 13% increase. However, net income dropped to $0.2 million from $4.8 million in the prior year, while adjusted EBITDA also fell to $6.8 million from $13.5 million. Operating expenses rose by 18% to $38.6 million. The company faces global supply chain challenges but has strong demand for its new technologies, including ClearRT™ and CyberKnife® products.

Accuray Incorporated (NASDAQ: ARAY) will announce its second-quarter fiscal 2022 financial results on January 26, 2022, after market close. A conference call to discuss the results will be held at 1:30 PM PT / 4:30 PM ET on the same day. Dial-in numbers for the call are provided, along with information about accessing a live webcast and replay. Accuray focuses on innovative radiation therapy solutions to address complex patient needs, enhancing treatment efficiency in oncology and neuro-radiosurgery.

Accuray Incorporated (NASDAQ: ARAY) received approval from Japan's Ministry of Health to market its CyberKnife^® Robotic Radiosurgery System for treating trigeminal neuralgia (TN). This expands access to a high-precision treatment already in use in the U.S. and EIMEA. TN, characterized by severe facial pain, often necessitates ongoing medical care. Notably, 93.5% of patients experience relief from TN after three weeks using CyberKnife. This approval paves the way for potential reimbursement under Japan's health insurance system, enhancing treatment options for TN patients.

Accuray Incorporated (NASDAQ: ARAY) announced valuable findings supporting its CyberKnife robotic radiotherapy platform, which has shown effective treatment for neurological diseases through stereotactic radiosurgery. A recent analysis of over 7,000 patients from Stanford University highlighted the platform's growing acceptance and ability to treat various brain and spinal lesions. The CyberKnife enables precise, non-invasive treatment, potentially improving patient outcomes and quality of life. Advanced features, including AI-driven technology, enhance treatment planning efficiency.

Accuray Incorporated (Nasdaq: ARAY) will participate in Stifel's 2021 Virtual Healthcare Conference on November 16, 2021, at 6:20 am PACIFIC / 9:20 am EASTERN. The management team's presentation can be accessed through the Accuray website post-event, with a replay available for about 90 days. Accuray focuses on innovating radiation therapy solutions aimed at improving patient outcomes in oncology and other complex cases. For more information, visit www.accuray.com.

Accuray Incorporated (NASDAQ: ARAY) reported a record net revenue of $107.4 million for Q1 Fiscal 2022, a significant increase from $85.3 million year-over-year, driven by a strong 39% rise in gross orders totaling $70.0 million. However, the company faced a GAAP net loss of $1.0 million, compared to a net income of $0.4 million in the prior year. Adjusted EBITDA decreased to $5.4 million from $9.0 million. Cash reserves also fell to $105.2 million, down $11.7 million since June 2021, primarily due to bonus payouts and debt repayment.

Accuray Incorporated (NASDAQ: ARAY) announced a study in Frontiers in Oncology indicating that its CyberKnife robotic radiotherapy platform significantly improves survival rates for early-stage breast cancer patients receiving accelerated partial breast irradiation (APBI). The study suggests that CyberKnife's delivery of APBI could reduce the risk of secondary lung cancers and improve patient outcomes compared to traditional techniques. Utilizing advanced technology, CyberKnife offers precise radiation delivery, enhancing treatment efficacy while minimizing damage to surrounding tissues.

Accuray Incorporated (NASDAQ: ARAY) reported preliminary financial results for Q1 fiscal 2022, showcasing significant growth. Revenue reached $107.4 million, up 26% year-over-year from $85.3 million. Gross orders increased 39% to $70 million. Despite a projected GAAP net loss between $2 million and $1 million, the adjusted EBITDA is estimated between $4.5 million and $5.5 million. The company raised its full-year revenue guidance to a range of $420 million to $427 million.

Accuray Incorporated (NASDAQ: ARAY) announced the unveiling of its new VOLO™ Ultra technology for the Radixact® System at ASTRO 2021. This advanced planning solution enhances treatment efficiency and quality, enabling clinicians to treat more patients. Key highlights include the integration of ClearRT imaging and RayStation software support for the CyberKnife platform. Accuray is focused on continuous innovation in radiation therapy, aiming to improve patient outcomes and expand treatment capabilities.